Earlier this year, Cellular Biomedicine Group Inc, or CBMG, a NASDAQ-listed biomedicine company, announced the acquisition of four novel chimeric antigen receptor T-cells (CAR-T) immuno-oncology technologies and clinical data from the Chinese PLA General Hospital, also known as the 301 Hospital, for the treatment of advanced lung cancer and blood cancer. CAR-T therapy is considered one…